Introduction to Japan’s Conditional Approval Q&A
According to the Q&A document issued by Japan’s Ministry of Health, Labour and Welfare (MHLW) on April 30, 2026, Japan has clarified the implementation of its revised Conditional Approval Policies for Pharmaceuticals under the Pharmaceuticals and Medical Devices Act (PMD Act). The Q&A supplements the February 27, 2026, notification on the handling of conditional approval and provides practical guidance on when the policies are applicable, what supporting data is acceptable, post-approval obligations, and circumstances that may lead to modification or revocation of approval.
The revised policies are designed to accelerate patient access to medicines with high unmet medical needs while maintaining scientific rigor through post-approval confirmatory requirements.
What Product is Applicable for the Conditional Approval Policies?
The Q&A explains that the conditional approval policies may be considered for products where approval can reasonably be supported by exploratory clinical evidence or alternative data, with the understanding that confirmatory evidence will be submitted after approval.
Potential candidates include:
To note, in principle, the policies are not applicable when the existing clinical trial results are considered adequate to establish efficacy and safety in the Japanese patient population, without necessitating any post‑approval obligations to submit further clinical evidence.
What Types of Data May Support Conditional Approval?
MHLW clarifies that exploratory clinical trial results are generally expected to support conditional approval applications, although other evidence may also be acceptable depending on the product.
Examples include:
Importantly, if sponsors plan to apply using interim analysis data, early consultation with the PMDA is strongly recommended to address risks, such as trial unblinding or changes in treatment environments, that may complicate interpretation.
Early PMDA Consultation Is Strongly Encouraged
The Q&A reinforces that sponsors should engage with PMDA before starting exploratory studies or before submitting an application to discuss:
These consultations may include discussions on the expected scope of post-marketing clinical trials, study objectives, timelines, and even possible restrictions on healthcare institutions authorized to use the product.
Notably, the final approval conditions are determined by MHLW and may change during review, even if preliminary agreement has been reached with PMDA.
Flexibility in Post-Approval Confirmatory Studies
Japan’s revised framework provides greater flexibility regarding post-approval requirements.
The required confirmatory studies:
In addition to clinical trials, Japan may also accept post-marketing investigations, medical databases (e.g., MID-NET), and patient registries to collect additional evidence.
Furthermore, results generated through post-approval studies may potentially be leveraged for:
Post-Approval Reporting and Disclosure Obligations
Marketing authorization holders are required to:
The Q&A also emphasizes transparency obligations. Results from required post-approval studies should be publicly disclosed, for example through:
Importantly, disclosure is expected regardless of whether the study is completed or whether approval status changes.
When Can Conditional Approval Be Modified or Revoked?
MHLW clarifies that post-approval study results will be reviewed based on:
Based on the evaluation and consultation with the Pharmaceutical Affairs and Food Sanitation Council:
Conclusion
Japan’s new Q&A on the conditional approval policies provides important practical clarification for global pharmaceutical companies seeking faster market access for medicines addressing serious unmet medical needs. The guidance signals a more flexible, globally aligned regulatory approach, including the acceptance of exploratory data, overseas confirmatory trials, and real-world evidence under appropriate circumstances.
For companies considering Japan as part of a global accelerated development strategy, early engagement with the PMDA and proactive planning for post-approval evidence generation will be critical to maximizing the opportunities offered by this revised framework.
Reference